INTEL: Eli Lilly lifts full-year revenue forecast to $91B-$92B after Q3 beat
Eli Lilly (LLY) raised its full-year revenue forecast to $91 billion to $92 billion from $85 billion to $87 billion after reporting third-quarter revenue of $24.40 billion, above the $22.52 billion analysts expected. Adjusted earnings per share came in at $7.48 against an estimate of $5.59.
The company cut the top and bottom of its full-year adjusted EPS range. It now expects $35 to $36 per share, down from $35.50 to $36.50. The quarter included acquired in-process R&D charges of $4.57 per share.
Mounjaro and Zepbound beat, Foundayo misses
Mounjaro revenue was $10.7 billion, ahead of the $9.95 billion estimate. Zepbound revenue was $5.35 billion against an estimate of $5.01 billion.
Foundayo was the miss. It brought in $184 million, short of the $231.2 million analysts had forecast.
Results against estimates
- Adjusted EPS: $7.48 vs $5.59 expected
- Revenue: $24.40 billion vs $22.52 billion expected
- Mounjaro: $10.7 billion vs $9.95 billion expected
- Zepbound: $5.35 billion vs $5.01 billion expected
- Foundayo: $184 million vs $231.2 million expected
The supplied figures do not say how much the acquired R&D charges affected the adjusted EPS guidance change, and they give no further detail on the revenue upgrade.
